Answers are grounded in this paper and cite their sources.
Expanded access program demonstrates antifungal efficacy in coccidioidomycosis, suggesting a potential treatment option.
Coccidioidomycosis is an invasive fungal infection that can disseminate and cause severe disease. Fosmanogepix ("gepix"), a first-in-class antifungal available via expanded access (NCT06433128), was successful in 8/11 patients (meningitis, 6/8 [75%]; non-meningeal dissemination, 2/3 [66%]) and was well tolerated for a median treatment duration of 208 days.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: